Co-Diagnostics, Inc. (CODX) Stock

Co-Diagnostics, Inc. (CODX) is a Healthcare stock trading at $1.16 (as of 2026-08-20), with a market capitalization of $7.25M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Co-Diagnostics, Inc. develops, manufactures, and sells molecular diagnostics reagents and tests that detect or analyze nucleic acid molecules. Its offerings include PCR-based diagnostic tests and platforms, multiplex assays for mosquito-borne disease identification, and additional molecular tools for infectious disease detection, liquid biopsy, and genetic trait testing in plant and animal genomes, plus a portable device intended to enable PCR testing at point of care and at home.

Understand Co-Diagnostics, Inc.: how it makes money

Co-Diagnostics develops, manufactures, and sells molecular diagnostics reagents and PCR diagnostic tests, detecting and analyzing nucleic acid molecules for targets such as COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and Zika.

The profit model is driven by recurring demand for PCR-based nucleic acid testing, through the company’s reagents and its Co-Dx PCR platform used in point-of-care and at-home settings.

Business quality (Weak): This dataset provides a clear business description, but it does not include reportable segment breakdowns or any operational KPIs, so investor focus metrics cannot be identified from the provided inputs.

Bull case

  • Broad PCR test and reagent offering across multiple infectious disease targets: The company provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and Zika, using nucleic acid detection and analysis.
  • Point-of-care and at-home use cases: Its Co-Dx PCR platform supports PCR testing to patients in point-of-care and at-home settings, which can support adoption beyond traditional clinical settings.

Bear case

  • Recent profitability metrics reported as deeply negative: For the period ending 2026-03-31, gross margin is reported as -32.8% and operating margin is reported as -6309.1%, which highlights significant cost and/or revenue pressure.
  • Limited visibility into operating drivers from provided data: No operational KPI labels or segment revenue breakdowns are provided here, making it harder to assess what specific operational metrics are driving performance.
Valuation — source: SEC EDGAR (first-party)
Price$1.16
Market Cap$7.25M
Price / Book0.57
Price / Sales12.02
FCF Yield-753.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$622489.00
Net Margin-7533.6%
Revenue Growth (YoY)-84.1%
EPS Growth (YoY)2742.7%
FCF Growth (YoY)-0.2%
Financial Health — source: SEC EDGAR
Altman Z-Score-10.11 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($322641.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEODwight H. Egan
Employees132
CountryUS
IPO Date2017-07-12

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Adagio Medical Holdings, Inc. (ADGM)
  • SeaStar Medical Holding Corporation (ICU)
  • Sintx Technologies, Inc. (SINT)
  • Intelligent Bio Solutions Inc. (INBS)
  • enVVeno Medical Corporation (NVNO)
  • Picard Medical, Inc. (PMI)
  • Autonomix Medical, Inc. Common Stock (AMIX)
  • Bluejay Diagnostics, Inc. (BJDX)
CODX earnings history · CODX institutional & insider holders · CODX KPIs & operating metrics · CODX financials · CODX investor presentations & press releases · CODX SEC filings · CODX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.